UNASSIGNED: Background.    Efficacy endpoints in @entity683 clinical trials may include clinical symptoms and virological measurements, although virology cannot serve as the primary endpoint. We investigated the relationship between @entity683 A RNA copy number and quantity of infectious viruses in hospitalized @entity683 @entity1 . Methods.    One hundred fifty @entity683 -infected, hospitalized @entity1 were included in this prospective cohort study spanning the 2012-2013 @entity683 season. Daily nasopharyngeal samples were collected during hospitalization, and @entity683 A RNA copy number and infectious viral titer were monitored. Results.    The decay rate for 50% tissue culture infectious dose (TCID50) was 0.51    0.14 log10 TCID50/mL per day, whereas the RNA copy number decreased at a rate of 0.41    0.04 log10 copies/mL per day (n = 433). The log ratio of the RNA copy number to the infectious viral titer within @entity1 changes significantly with -0.25    0.09 units per day (P = .0069). For a 12-day observation period, the decay corresponds to a decline of this ratio of 3 log @entity683 RNA copies. Conclusions.    Influenza RNA copy number in nasal swabs is co-linear with culture, although the rate of decay of cell culture-based viral titers was faster than that observed with molecular methods. The study documented a clear decreasing log ratio of the RNA copy number to the infectious viral titer of the @entity1 over time.

A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza']
@entity1 :: (9606,Species) :: ['Patients']
